• Latest Writing
  • Models
  • Old Posts
  • Contact
Menu

The Non-Consensus

  • Latest Writing
  • Models
  • Old Posts
  • Contact

Note: I’m transitioning my writing to substack; if you’d like to subscribe, please do so there!

Recent stock posts

Stocks
AstraZeneca: A Strong Oncology Pipeline with Higher Expectations
about 5 years ago
Clovis Oncology: Waiting on PARP Traction; Competition a Concern
about 5 years ago
Biogen: Aducanumab Questions Linger After CTAD, but Trading Opportunities Exist
about 5 years ago

About the blog

I am a former Wall Street analyst writing for fun. I'm attracted to the ideas that no one's talking about. 

Follow me on Twitter @thenonconsensus

Find posts by ticker/tag

  • AAP 1
  • AAPL 2
  • ABBV 2
  • ABT 2
  • ADBE 1
  • AGN 3
  • ALKS 1
  • AMGN 2
  • AMRN 1
  • AMZN 7
  • ATVI 1
  • AZN 2
  • AZO 1
  • BBBY 8
  • BIIB 3
  • BLUE 1
  • BMY 1
  • CELG 2
  • CLVS 1
  • CMG 4
  • COST 1
  • ETSY 1
  • FB 5
  • FDS 1
  • GILD 2
  • GOOGL 1
  • GSK 3
  • HD 9
  • JNJ 3
  • LLY 1
  • LOW 3
  • LULU 1
  • MDT 2
  • MRK 2
  • MTCH 1
  • MYL 5
  • ODP 1
  • ORLY 1
  • PFE 3
  • PTON 1
  • RDFN 1
  • REGN 2
  • RETA 2
  • RH 1
  • SBUX 1
  • SCSS 1
  • SHLD 1
  • SPLS 3
  • TEVA 2
  • TSLA 6